Study provides new evidence of weight loss benefits for type 2 diabetes patients

Researchers in the School of Population Health at RCSI University of Medicine and Health Sciences have provided new evidence of the health benefits of weight loss efforts that lead to diabetes remission for type 2 diabetes patients.

FDA lifts partial hold on Phase III plans for rare ataxia drug – Pharmaceutical Technology

The company plans to enrol patients into the Phase III NEAT study in Q2 2024. Credit: Billion Photos via www.shutterstock.com Quince Therapeutics has announced that

October 2, 2023

CHMP recommends rejecting Amylyx ALS drug, pitting EMA against FDA and Health Canada

The European Medicines Agency recommended that Amylyx Pharmaceuticals’ ALS drug be rejected within the EU. The drug, known as Relyvrio in the US and Albrioza

June 24, 2023

Advent receives NIH grant for bronchopulmonary dysplasia therapy

Bronchopulmonary dysplasia is a rare disease impacting premature infants. Credit: Ro_Ma_Li / Shutterstock.com. Advent Therapeutics has received a small business innovation research grant worth $3m

July 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.